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EXECUTIVE SUMMARY 
Heath, Margaret. Atherosclerosis in HIV Positive Patients: A Clinical Practice Guideline 
for Cardiovascular Risk Assessment and Treatment. Unpublished Doctor of 
Nursing Practice Capstone Project, University of Northern Colorado, 2017. 
 
 
As modern medicine allows for an increase in lifespan, patients with Human 
Immunodeficiency Virus (HIV) face the same chronic health issues as other aging adults. 
Among the top killers of older adult HIV patients is atherosclerosis. The following 
review of literature will support the belief that HIV patients are at a higher risk for 
atherosclerosis due to their chronic inflammatory state. This state in which the immune 
response is elevated for a prolonged period of time provides an optimal environment for 
the development of atherosclerotic plaques, as the research evidence will demonstrate. 
The following guideline has been designed to assist providers in assessing an individual’s 
risk and appropriate interventions in order to preserve the quality of life that this 
population cherishes deeply.  
There has been a growing interest in this topic as anti-retroviral therapy (ART) 
becomes more targeted and effective. The importance of this guideline is to identify high 
risk patients and equip providers with the knowledge to implement appropriate 
interventions as quickly as possible. Early intervention will drastically decrease the levels 
of atherosclerotic plaques in HIV positive patients. In conjunction with lifestyle 
modifications, adherence to anti-retroviral therapy and initiating statin therapy if 
appropriate, these high risk patients would be adequately prepared for the aging process.  
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Patients with human immunodeficiency virus (HIV) exhibit a two-fold increased 
risk of atherosclerotic plaque development (Fitch et al., 2013). Because of this, the 
primary goal for practitioners has been to identify patients who were deemed high risk 
and implement appropriate measures to prevent negative sequelae of cardiovascular 
disease related to plaque formation. As patients with HIV live longer, the early detection 
and treatment of cardiovascular disease must take precedence in the care plan for this 
population.  
 According to a cross-sectional study of 60 infected women and 30 non-HIV 
infected women ages 18-60, HIV positive women have had an increased risk of 
developing non-calcified plaques resulting in myocardial infarction and atherosclerosis 
(Fitch et al., 2013). This study also correlated specific factors of the HIV disease process 
(inflammation and immune activation) to the production of atherosclerosis. Further, this 
risk could be compounded by lifestyle factors such as obesity, smoking, and frequent 
infections. 
 Furthermore, the Journal for Vascular Health and Risk Management examined 
HIV positive patients who were concurrently diagnosed with cardiovascular disease and 
found that chronic inflammation secondary to HIV increased the severity and rate of 




Background and Significance 
 Evidence has supported screening during a primary care wellness visit for an HIV 
patient that would begin with a fasting lipid panel and obtainment of vital signs as well as 
screening for hyperlipidemia (Depairon et al., 2001; Fitch & Grinspoon, 2011; Hulten, 
Mitchell, Scally, Gibbs, & Villines, 2009; Maggi et al., 2009). These screening 
techniques should be utilized for every patient, regardless of risk factors. Also, because 
advanced age, sex, smoking status, and inflammatory markers all influence 
cardiovascular risk in HIV positive patients (Depairon et al., 2001; Fitch et al., 2013; 
Maggi et al., 2009), lifestyle modifications should be an integral part of every patient’s 
care plan. Age greater than 65 years has been identified as a high-risk factor, and elderly 
HIV patients must receive frequent and comprehensive screenings to prevent heart 
disease. 
The Framingham Risk Score (FRS) calculates the 10-year risk of coronary artery 
events based upon the investigation of risk factors including sex, age, total cholesterol 
level, high-density lipoprotein (HDL) level, systolic blood pressure, blood glucose level, 
and smoking status. As a valid tool to predict atherosclerosis risk in HIV patients 
(Maggie et al., 2009; Martin et al., 2005), the FRS should be assessed annually to detect 
cardiovascular disease earlier in this high risk population (Cheruvu & Holloway 2014). 
New practice recommendations advised risk factors compilation into a FRS to determine 
the level of risk, then diagnostic screening by carotid intima-media thickness or coronary 




Patients with HIV should be carefully monitored for compliance to the ART 
regimen. These drugs have diminished HIV mortality rates and have been found to 
reduce chronic inflammation and immune activation (Beltran et al., 2015). 
Problem Statement 
Health care providers must have access to a comprehensive guideline that 
addresses all aspects and characteristics of the HIV disease process (endothelial 
dysfunction, chronic inflammation and immune system activation, and metabolic 
abnormalities). Coinfections have both contributed to and accelerated atherosclerosis; 
thus, prevention of cardiovascular disease, treatment of chronic inflammation, and 
continuation of ART would be key components to achieving better quality of life (Beltran 
et al., 2015). Patients with HIV should be managed as a chronic infectious disease, as 
high viral loads have been associated with endothelial dysfunction and the development 
of atherosclerosis (Muhlestein, 2011). Treatment compliance has been influenced by 
stigma, access to care, personal empowerment, and available support systems (Cahill & 
Valadez, 2013). For this reason, health care providers must provide holistic care to the 
HIV patient and encourage self-management of this chronic disease. Therefore, this 
guideline has addressed these components and has also included the expert opinions of 
those on the frontline of care for this population.  
Theoretical Framework: The Stetler 
Model 
 
For the purposes of this project, the Stetler model was utilized to determine 
availability of resources and the readiness of the providers being included in this project 
(Terry, 2015). The five steps of the Stetler model allowed for the translation of research 




identification of the problem in current practice. This project aimed to give providers one 
guideline which included all the aspects recommended by current literature as well as the 
provider preferences for additions to existing guidelines.  
Phase II included a systematic review of literature which supported the 
development of a guideline directing the diagnosis and treatment of atherosclerosis in 
HIV patients. This guideline was also evaluated by the Delphi participants and adjusted 
as needed. Delphi participants included one nurse practitioner, one physician assistant, 
and one medical doctor. Including three different professions resulted in inter-
disciplinary collaboration which ultimately increased the applicability of the results of the 
Delphi survey. Two rounds of surveys were administered, the first being in Phase II and 
the second being in Phase III.  
Phase III was the evaluation and decision-making stage which included the 
second Delphi method questionnaire to identify areas which required revision and 
addendums to the guideline. Participants in the Delphi survey were also asked to reach an 
agreement on the items they wanted included in the guideline. The agreement reached in 
the survey directly influenced the development of the guideline. Stakeholders in this 
project included all providers who participated in the Delphi survey and those who may 
utilize the final guideline in their practice. The stakeholders’ willingness to change was 
also addressed in this stage and all were eager to participate.   
Phase IV included translation and application of the guideline. During this stage, 
the guideline was created for use at a clinic which focused on the primary care of HIV 
positive patients. Should a clinic with this composite choose to adopt it, the guideline 




stage was completed after the conclusion of this capstone project as additional time was 
necessary to receive approval.  
 Lastly, Phase V evaluated the clinical practice guideline and included a final 
questionnaire for providers after 3 weeks of use regarding its helpfulness and 
applicability. In this stage, the objectives were evaluated to determine the project’s 
success.  
Literature Review 
The analysis of the literature included 19 scholarly articles. Seven of these articles 
supported the suspicion that there were links between atherosclerotic plaque development 
and chronic inflammation and specifically addressed the key risk factors of 
atherosclerosis development. Of the treatment recommendations, preventative screening 
commonly included the following tests: Carotid intima media thickness testing, coronary 
computed tomography angiography, and blood laboratory testing of inflammatory 
markers in high risk patients.  
The majority of the studies evaluated demonstrated a positive correlation between 
chronic inflammatory markers and atherosclerosis. This link validated the fact that HIV 
patients, who have had prolonged elevation of their inflammatory markers, would be 
susceptible to atherosclerosis. Working off of this premise, there was additional literature 
examined to determine methods to decrease these risk factors such as the continuation of 
ART therapy, the initiation of statin therapy, and lifestyle modifications. The review of 
literature further supported the use of the Framingham Risk Score (FRS) in order to 
assess the patient’s age and high sensitivity C-Reactive Protein (hs-CRP) count to 







































Regardless of risk level, screening during a primary care wellness visit for an HIV 
patient should begin with a fasting lipid panel and obtainment of vital signs (Depairon et 
al., 2001; Fitch & Grinspoon, 2011; Hulten et al., 2009; Maggi et al., 2009). Also, 
advanced age, sex, smoking status, and inflammatory markers all influence 
cardiovascular risk in HIV positive patients (Depairon et al., 2001; Fitch et al., 2013; 
Maggi et al., 2009). Because age greater than 65 years has been identified as a high-risk 
factor, elderly HIV patients must receive frequent and comprehensive screenings to 
prevent heart disease. Therefore, being an older adult and/or current smoker would 
automatically constitute high risk treatment recommendations.  
In developed countries, HIV positive patients with a preliminary CD4 count 
greater than 200 and compliant with long-term antiretroviral treatments (ART) have 
demonstrated life expectancies past 70 years of age (Cahill & Valadez, 2013). Because of 
this, a CD4 count less than 200 should result in that patient being categorized as high 
risk, independent of other factors.  
An extensive study by the American Heart Association and Center for Disease 
Control demonstrated the inflammatory marker known as the high sensitivity C-Reactive 
Protein (hs-CRP) as a strong indicator of cardiovascular disease risk in HIV patients, 
(with a 10-20% risk of developing heart disease within the next 10 years), as well as a 
predictor of coronary events in patients with established heart disease (Pearson et al., 
2003). Therefore, an hs-CRP should be obtained and, if greater than 3.0 mg/L, the 





Once deemed high risk, these patients should be carefully monitored for 
Antiretroviral Therapy (ART) regimen compliance. These drugs have diminished HIV 
mortality rates and have been found to reduce chronic inflammation and immune 
activation (Beltran et al., 2015). Due to adverse metabolic effects of dyslipidemia and 
insulin resistance, ART, especially protease inhibitors (PIs), has remained under scrutiny 
for their potentially detrimental effects. Nevertheless, a consensus of research studies 
have revealed a weak relationship between HIV positive patients using protease 
inhibitors and subsequent atherosclerosis development, supporting their continuation 
(Beltran et al., 2015; Hulten et al., 2009; Martin et al., 2005). While PI use has not 
modified values of Coronary Artery Calcification (CAC) or carotid plaque in HIV 
positive patients (Hulten et al., 2009), smoking and hyperlipidemia have been identified 
as having a causal relationship with thickened CIMT (Depairon et al., 2001). This 
supported not only continuation of ART therapy in high risk patients but further 
supported measures to increase medication regimen adherence. Methods in which 
providers could assist patients with this are discussed at a later time.  
Statin therapy has been another debated treatment option. Statins have been a 
recommended practice for individuals greater than 75 years old with cardiovascular 
disease, diabetes, and/or high low-density lipoprotein (LDL) levels (Miedema et al., 
2015). Yet, research has failed to indicate whether these findings were applicable to HIV 
positive patients. Another study highlighted how targeting high LDL-cholesterol levels in 
HIV infected patients were safe and effective in decreasing the FRS, however, failed to 




2009). Rosuvasatin has currently been a lipid-lowering therapy undergoing clinical 
laboratory analyses to determine its safety in HIV patients (De Lorenzo et al., 2009). 
Niacin, fibrates, and fish oil have been suggested as safe medications to treat 
dyslipidemia (Fitch & Grinspoon, 2011) and could be helpful in the management of LDL 
levels in this population. Patients with HIV who were on statins would require frequent 
fasting lipid levels, liver function tests, and creatine kinase levels, thus, the following 
alternatives which require less monitoring have been encouraged as a first line treatment: 
lifestyle modifications, switching the type of ART, and adding fibrates (Cheruvu & 
Holloway, 2014). Research has illuminated concern that concurrent ART and statin 
therapy could cause liver toxicity (Cahill & Valadez, 2013; Depairon et al., 2001). 
Because of this potential harm, the implementation of statin therapy in high risk patients 
has been recommended only under the following conditions: the aforementioned first line 
suggestions were ineffective, the patient received frequent laboratory monitoring, and a 
thorough medical history was obtained.  
The major causes of death in elderly HIV patients have included cardiovascular 
disease and liver disease, both adverse effects of long-term ART (Cahill & Valadez, 
2013). For this reason, it has been advised to receive Computed tomography (CT) 
coronary angiography and stress echocardiography to assess for coronary artery disease 
in HIV patients using long-term ART (Cheruvu & Holloway, 2014). In summary, this 
new proposal for treatment suggested continuation of ART as the primary medication in 
HIV patients, yet long-term use would require further testing to confirm safety and 




Many HIV positive patients have exhibited significant risk factors for 
atherosclerosis such as obesity, lack of exercise, diabetes, hyperlipidemia, smoking, poor 
diet, ART, and sedentary lifestyle. Effective lifestyle adaptations that could decrease 
atherosclerosis risk in HIV patients included: weight reduction, more than 30 minutes of 
daily exercise, smoking cessation, and consuming a healthy diet (Cheruvu & Holloway, 
2014; Depairon, 2001; Fitch & Grinspoon, 2011; Hulten et al., 2009). To lessen insulin 
resistance, patients should be screened via oral glucose tolerance tests, switched from PIs 
to another form of ART with less metabolic effects (Cheruvu & Holloway, 2014), and 
treated with Metformin (Cheruvu & Holloway 2014; Fitch & Grinspoon, 2011). When 
treating insulin resistance and dysplipidemia, liver and kidney functioning would require 
careful monitoring (Fitch & Grinspoon, 2011). In summary, a new practice guideline 
would enhance the treatment of HIV through nutrition and lifestyle modifications to 









The primary goal for practitioners has been to identify patients who were deemed 
high risk and implement appropriate measures to prevent negative sequelae of 
cardiovascular disease related to plaque formation. This project aimed to create a 
guideline for providers which included evidence-based recommendations for screening 
and subsequent treatment of atherosclerosis in HIV patients.  
Project Objectives 
The aforementioned evidence supported the need for aggressive preventative 
screening and treatment in this population, which this guideline aimed to address. Three 
objectives were identified to direct this project and the development of said guideline.  
1. Evaluate utilization of current guidelines which direct atherosclerosis 
screening and treatment.  
a. Assess for deficits in current guidelines 
b. Determine differing clinical guideline preferences among providers 
by using the Delphi method 
2. After reaching a consensus among the Delphi participants, create a 





a. Establish current recommendations regarding screening and 
treatment of atherosclerosis in the HIV positive population  
3. Assess for the guideline’s usefulness, effectiveness, and applicability 
according to the providers who implement it 
Project Design and Method 
 This project was a non-experimental, quality improvement project which aimed to 
translate current research evidence into practice. The Delphi model was utilized to obtain 
unanimity among providers regarding the aspects of this guideline. The Delphi model 
uses questionnaires to obtain commonalities and ultimately consensus among a panel of 
experts. Participation in this project was voluntary and the panelists will remain 
anonymous.  
Setting and Resources 
 This project was completed for a generic clinic setting and made available to 
primary care providers. Upon completion of this capstone project, these providers were 
invited to implement the guideline as part of the clinical reference directory at their 
respective clinics.  
 There was no financial support required for this project as it was completed as 
part of the requirements of the Doctor of Nursing Practice degree. 
Protection of Human Subjects 
 This project did not involve a chart review or a database of patient information. 
Providers who were included on the panel of experts were encouraged to utilize the 






 Phase I: Preparation 
o Topic identified: August 2016 
o Capstone committee established: January 2017 
o Committee approved: March 2017 
 Phase II: Validation 
o Literature review: December 2016 
o Capstone proposal approved: June 30, 2017 
 Phase III: Evaluation 
o Approval from the University of Northern Colorado Institutional Review 
Board: September 15, 2017 
o First Delphi questionnaire and informed consent sent to providers: 
September 16, 2017 
 Phase IV: Translation of Evidence into Practice 
o Synthesis of literature, evaluation of current practice guidelines: 
completed September 30, 2017 
o Cardiovascular Screening and Treatment Guideline developed: September 
20, 2017 
 Phase V: Evaluation 




Feasibility and Sustainability 
 The literature review and provider input via Delphi survey was used to direct the 
development of this guideline. Once it was completed, providers were able to access the 









 Three objectives were established to evaluate the success of this project. The 
capstone ultimately aimed to provide a comprehensive, user-friendly guideline to 
providers who were caring for HIV patients.  
Objective One 
 The current guidelines and tools used both nationally and locally were evaluated. 
They were reviewed specifically in light of the most current research evidence (obtained 
during the literature review) and then all providers were asked to complete the first 
Delphi questionnaire.  
Objective Two 
Research evidence and the results of the first Delphi survey were evaluated for 
usefulness within the context of this guideline. Providers were invited to make requests of 
information to include in this guideline.  
Objective Three 
Objective three included the creation of the guideline as well as the assessment of 
usability and overall provider perception by means of the questionnaire. Additions and 
adjustments were made to the guideline. The final Delphi questionnaire was sent out to 






RESULTS AND OUTCOME STATEMENTS 
 This Capstone project aimed to assist providers in determining the best course of 
action for HIV positive patients who require cardiovascular risk assessment and 
subsequent treatment. There were currently several guidelines that provided direction, but 
all have differences in the screening techniques and treatment recommendations. The first 
objective of this project was to collect data and evaluate existing guidelines in order to 
compare and contrast current recommendations being implemented by providers.  
Objective One: Results from Literature 
Review 
 
Objective one was achieved through a comprehensive literature review wherein 
guidelines were weighed and measured against existing literature. Several commonalities 
found throughout the various guidelines were implemented into this project.  
National guidelines were aimed to initiate screening for the high risk patients, as 
well as implement treatment strategies to prevent or slow progression of negative 
sequelae. The evidence and current guidelines overwhelming favored early and frequent 
evaluation of HIV patients. If the patient exhibited additional risk factors such as 
advanced age, smoking, frequent co-infections, or existing cardiovascular disease, this 
warranted more in-depth diagnostic testing such as carotid intima-media thickness 
(CIMT) testing and plaque visualization testing via computed tomography (CT) 




 The most prominent medical databases were scrutinized and five guidelines were 
found to be commonly utilized in the treatment of dyslipidemia and cardiovascular 
disease in the HIV population. The guidelines put forth by the following agencies were 
closely examined: the U.S. Preventative Services Task Force (USPSTF), the American 
College of Cardiology/American Heart Association (ACC/AHA), the Agency for 
Healthcare Research and Quality (AHRQ), the National Institute of Health (NIH), and the 
Infectious Disease Society of America (IDSA), respectively. 
U.S. Preventative Services Task 
Force (USPTF) 
 
This agency provides direction and recommendations regarding the early 
screening and subsequent treatment of cardiovascular disease and dyslipidemia. The 
USPSTF reported reviewing literature regarding diagnostic accuracy and the efficacy of 
various treatment options. Although this guideline did not specifically mention the HIV 
population, it did summarize recommendations for individuals above 20 years of age and 
placed them into a higher risk category. This risk level would also apply to patients who 
had chronic elevation of inflammatory mediators.  
The recommendation concluded that there was evidence to support the lipid 
measurement of men and women who were candidates for therapy and the benefits of 
screening and treating lipid disorders in high risk patients overwhelmingly outweighed 
the potential harms. The preferred tests to screen for dyslipidemia were a total cholesterol 
level and a HDL-C level. Abnormal results should be confirmed by repeated testing and 




American College of Cardiology/ 
American Heart Association 
(ACC/AHA) 
 
The ACC/AHA also produced a prevention guideline for the assessment of 
cardiovascular risk in 2013. The guideline provided an estimated 10-year risk 
stratification based on the patient’s age, gender, and race. If completion of the 
quantitative risk assessment resulted in unclear treatment recommendations, the patient’s 
family history, coronary artery calcification (CAC) score, and high sensitivity C-Reactive 
Protein (hs-CRP) levels should be obtained to inform medical decision making. The 
guideline recommended the assessment of cardiovascular risk factors every 4 to 6 years 
in patients 20-79 years of age who did not have cardiovascular disease (CVD).  
The guideline was summarized in an algorithm that assessed for current CVD, the 
patient’s age as well as the 10-year risk using the Pooled Cohort Equation. The guideline 
assessed the 10-year risk based on the following factors: smoking and diabetes status, 
cholesterol levels, the presence of hypertension, age, gender, and race. Although the 
recommendation did not specifically address HIV status, many patients with HIV had 
hyperlipidemia and thus, would be captured in the high risk stratification.  
The Agency for Healthcare Research 
and Quality-American Association 
of Clinical Endocrinologists 
(AHRQ) 
 
This guideline was published in 2012 and updated a previous version from 2000. 
In a four-step process, the AACE recommended a global risk assessment, screening based 
on age, selection of screening tests, and the treatment of specific diagnostic findings, 
respectively. The target population was anyone above the age of 2 and those at risk or 




specific inflammatory markers were considered in the evaluation of CVD risk, they were 
not recommended to be included in the screening process. This may be partly a result of 
cost consideration and the expense of obtaining these laboratory results. However, CRP 
levels were recommended in the screening process of adults with dyslipidemia.  
The guideline also made an addendum for specific high-risk populations and 
recommended close monitoring of these patients. For all patients, the lipid status should 
be reassessed 6 weeks after initiation of pharmacotherapy and then 6 to 12 month 
intervals. Additionally, if patients did not initially respond to pharmacotherapy, the 
clinician should consider combination therapy such as Niacin added to an existing 
Simvastatin regimen.  
The National Institute of Health 
(NIH) 
 
In step one of this seven-step guideline, the clinician was instructed to obtain a 
complete lipoprotein profile on the fasting patient. After the classification of LDL, total, 
and HDL cholesterol, the provider identified the presence of other atherosclerotic disease 
risk factors. In step three, the presence of major risk factors were established. These 
included positive smoking status, hypertension, advanced age, and positive family history 
for CVD. The Framingham Risk Assessment tool was employed to assess 10-year risk. 
After this, the clinician could determine the patient’s risk category and initiate therapeutic 
lifestyle changes, pharmacotherapy, or combination therapy if appropriate.  
Infectious Diseases Society of America 
(IDSA) 
 
This guideline specifically addressed the abnormalities of lipid metabolism in the 




total cholesterol and an increase in serum triglycerides were associated with advanced 
HIV disease and contributed to an elevated risk of CVD. The guideline recommended 
obtaining a fasting lipid profile followed by the assessment of coronary artery disease 
risk. The implementation of lifestyle modifications was recommended as a preliminary 
step, but the alteration of ART or initiation of lipid-lowering medication was suggested if 
the non-pharmacological methods are ineffective. 
Objective Two: Results from Delphi 
Questionnaire 
 
The Delphi questionnaire was utilized to complete objective two by obtaining 
consensus among current providers who, through their clinical practice experience and 
research knowledge, were willing to participate in the formation of this guideline. The 
goals of the Delphi survey were to address areas in which current guidelines were 
insufficient or lacking and to utilize provider feedback to increase the usability of this 
guideline. Participants represented three different specialties: nurse practitioner, 
physician assistant, and a physician. All providers who participated in the survey were 
currently practicing and had at least 4 years of experience. Additionally, the geographical 
locations in which these providers practiced spanned across state lines. These factors 
added to the usability and diverse applicability of the guideline as it was fitting for a 
variety of different patient care settings because of the diversity of providers and 
locations included in its creation. 
 Questions included in round one of the survey addressed the provider location of 
current clinical practice, discipline, and specialty. The survey also inquired about whether 
the provider felt like a specific guideline for cardiovascular risk in HIV patients was 




time did they perceive providers were following it. All but one participant said that the 
recommended guidelines were followed by providers “almost always.” They were also 
asked about the frequency of which HIV patients were screened for cardiovascular 
disease in their practice. Responses to this question varied greatly depending on the 
location and type of practice. Providers at specialty clinics caring exclusively for HIV 
patients said that, at least 70% of the time, patients underwent some method of screening 
annually, however, in the family practice setting, the response indicated that they simply 
did not know and could not provide a percentage. 
Finally, the survey asked participants to indicate which of the following they 
would like to have included on a guideline designed to screen for HIV cardiovascular 
risk: Age, current CD4 count, current white blood cell count, length of time since HIV 
diagnosis, family history as it pertained to cardiovascular health, presence of substance 
abuse (alcohol, tobacco, recreational drugs), and presence of current symptoms (dyspnea, 
chest pain, dizziness, hypertension). They were asked to add any other items that they 
would like to see in the guideline. 
Once the Delphi responses were returned, the data was recorded by the primary 
investigator. Nearly all responses identified age, family history, substance abuse, and 
current CD4 count as important to include. Additionally, they requested that HDL and 
LDL levels, the presence of an Abacavir regimen, BMI, current diabetes, and viral load 
should be added to the guideline (Appendix A).  
Objective Three: Assessment of Guideline 
Usability and Provided Perception 
 
Objective three included finalizing the Delphi questionnaire and designing the 




items to be included in the guideline and addressed further testing to be completed on 
patients who wee deemed “high risk” based on the standards of said guideline. All agreed 
that, at minimum, an EKG should be done and, if the patient was symptomatic or 
hypertensive, further testing such as an echocardiogram, blood work, and a stress test 
may be warranted. The treatment plan from this point forward would be based on 
provider preference and would be case dependent; therefore, this was only briefly 
addressed in the guideline. Upon in-depth review of the surveys, it was determined that 
the value of the guideline was in its ability to identify high risk patients who may have 
otherwise gone undetected rather than determine treatment regimens thereafter. 
 Therefore, the guideline created in partial completion of objective three included 
the items that the Delphi survey participants agreed upon, along with the addition of 
clinical parameters which determined if a patient should be classified as “high risk” or if 
they fell within defined parameters and could proceed with bi-annual monitoring for 
above mentioned risk factors. However, should the patient be outside of the parameters 
for three or more items within the guideline, they would be deemed high risk and should 
undergo further evaluation including an immediate EKG and additional follow-up care 
including nutrition counseling and possible cardiology referral. 
Key Facilitators 
 Key facilitators for this projects’ success included the continual collection of 
literature. Committee members contributed greatly to the data collection process and 
provided key articles that assisted in the development of the guideline. Without the eager, 
thorough, and prompt responses from the panel of experts on the Delphi surveys, this 




Institutional Review Board approval was integral to the completion of this project (see 
Appendix B). 
Key Barriers 
 Barriers arose during the process of creating the guideline for a specific clinic. 
Although this was preferred by the author and committee, complications began while 
trying to organize the logistics of a clinical rotation. Although seemingly detrimental, the 
guideline was designed in such a way to be applicable within a variety of patient settings. 
 The author also experienced difficulty with the time constraints relating to the 
turnover of round one and two of the Delphi survey and this nearly posed a substantial 
delay to the completion of the project. However, due to the prompt replies from the panel 








IMPLICATIONS FOR PRACTICE 
Recommendation for Guideline 
Implementation 
 
As previously mentioned, this guideline would have a wide range of applicability 
due to its design. While appropriate to use at a family medicine clinic, it would be most 
useful at a specialty HIV/AIDS clinic where the patient was closely followed. The 
guideline was intended primarily for use at annual physical appointments or anytime 
when a full health assessment was being done. Ideally, this guideline would be re-
assessed every 6 months as many of the risk factors could change rapidly but, at least, it 
should be assessed every 12 months. 
Should a clinic choose to implement this guideline into practice, it would be 
recommended that they first use it alongside the guideline they were currently using. Not 
only would this make the provider’s transition into switching guidelines more smooth, 
but it would shed light on the areas in which the guideline would still lacking, or perhaps 
its strengths, and may provide the author with suggestions for further improvement. 
 Finally, before introduction of the guideline to providers, it would be 
recommended that there be a staff in-service designed to educate and answer questions 
about the guideline implementation process. Ultimately this guideline has been designed 




Ongoing Activities and Evaluations Outside 
the Scope of the Doctor of Nursing 
Practice Project 
 
Based upon discrepancies in evidence, further research recommendations include: 
methods for safe statin therapy use in this population, the effects of hormone therapy 
(specifically estrogen) on atherosclerosis development, and finally the most indicative 
inflammatory marker to gauge atherosclerotic risk in HIV patients. Another suggestion 
for research would be to examine in detail the different ART regimens to determine if 
drugs other than protease inhibitors could improve patient outcomes with less metabolic 
effects. More research would be necessary to discover the risk-benefit relationship 
between ART used and statins in the elderly HIV patient, as quality of life usually 
becomes a higher priority than lifespan in this population. Additionally, there would be 
ongoing research to delineate between the various root causes of cardiovascular disease 
in these patients. Additionally, family medicine clinics should equip their providers with 
education regarding HIV and heart health. Providers should have heart health educational 
pamphlets readily available to give to patients. 
 Ideally, HIV patients would be followed by providers specializing in HIV or 
infectious disease because they require tailored care plans and close monitoring. Regular 
and consistent follow-up would be critical to health promotion and disease prevention in 
this population and, therefore, should be an integral part of their care plan. 
It is recommended that at the conclusion of the five year trial period a 
retrospective chart review be conducted in order to collect data and record patient 
outcomes. Data obtained would include all patients flagged as high risk according to the 




ordered for these patients and what was the clinical outcome? The result of those 
interventions would be important to include, as well as the current treatment plan as it 
pertains to cardiovascular health. This data could then be used to examine which areas of 
the guideline were still weak, as evidenced by the presence of risk factors that go 
undetected or by patients that incur a cardiovascular event but were not identified as high 
risk. A chart review and subsequent results comparison that reveals patients flagged as 
high risk who had risk factors that were previously unaddressed would demonstrate the 
usefulness of this guideline. Ongoing risk-factor analysis would be critical to the 
successful implementation and evaluation of this project.  
Five Criteria for Executing a Successful 
Capstone Project 
 
 A Doctor of Nursing Practice Capstone project involves five essential criteria 
explained as the “acronym EC as PIE” (Waldrop, Caruso, Fuchs, & Hypes, 2014, p. 301). 
The first step is the enhancement of health or practice outcomes as well as health policy. 
Next is the culmination of practice inquiry, followed by the development of partnerships 
and the implementation or translation of research evidence into practice. Finally, the 
process is completed by the evaluation of healthcare, practice, or policy outcomes 
(Waldrop et al., 2014). 
For the purposes of this project, the above criterion was met by first identifying 
the need for a concise, user-friendly guideline that could assist providers in treating and 
screening for atherosclerosis in HIV patients. Secondly, the author investigated 
commonly used guidelines in the practice setting, as well as utilizing the Delphi method 
to integrate provider preferences into the development of the guideline. Partnerships were 




understand the barriers and pitfalls of existing guidelines. Perhaps more importantly, the 
partnerships allowed for a deeper understanding of the intricate details of care as it 
pertains to the HIV population. Finally, the implementation and evaluation of this 
guideline as outlined above. This process would extend beyond the time constraints of 
this project but would be foundational to the improvement of the guideline. 
Summary 
The purpose of this guideline was to foremost increase the lifespan of HIV 
patients. By equipping providers with a guideline that was comprehensive and user-
friendly, high risk patients would be readily identified and more closely monitored. 
Because of its simplicity and wide range of applicability, family medicine providers 
would hopefully be more comfortable with the complex and possibly daunting task of 
caring for HIV patients. 
With additional time and feedback from those implementing this guideline, in the 
future it may be used as a stepping stone for further treatment initiatives or assistive tools. 
Providers should be encouraged to use this tool alongside their existing guideline(s) of 
choice and carefully consider all aspects of each individual patient condition prior to 
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GUIDELINE FOR CARDIOVASCULAR RISK ASSESSMENT 






GUIDELINE FOR CARDIOVASCULAR RISK ASSESSMENT 
IN HIV POSITIVE PATIENTS 
 
 
Which of the following applies to the patient? (Check all that apply) 
 
____ 60 years or older  
____ Positive history of cardiac condition (MI, CHF, HTN)  
____ Length of time since HIV diagnosis is greater than 5 years 
____ First-degree relative with MI history before the age of 50 
____ Substance abuse or tobacco history of any duration 
____ HDL level less than 40mg/dl and LDL level greater than 160mg/dl 
____ Viral load that exceeds one million copies/ml within the last six months  
____ Not currently on Abacavir regimen 
____ BMI greater than 25 




If the patient has three or more of the above risk factors, they are considered high risk. 
Proceed to the following algorithm: 
 
 
Is the patient currently hypertensive or experiencing possible cardiac symptoms 
(dizziness, dyspnea, shortness of breath, chest pain)? 
 
 


















Instruct patient to 
monitor daily blood 
pressure for further 
evaluation. Initiate 
antihypertensive 
regimen if needed.  
Immediate EKG 
rhythm interpretation 
and cardiac enzyme 
lab work. Consider 
echocardiogram, stress 
test, cardiology 
consult if indicated  
Continue to repeat this 
evaluation and 
monitor patient for 
additional symptoms 
or hypertension every 
three months. Order 
nutrition consult and 
provide heart health 
education (per clinic 
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